|
| Press Releases |
|
 |
|
| Monday, February 3, 2025 |
|
|
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies |
| National Center for Geriatrics and Gerontology and Eisai Co., Ltd. announced today that Eisai has created the "Guidance on Reducing the Risk of Cognitive Decline and Nutrition" and the "Handbook for Developing Home Delivery Meals/Meal Kits that Contribute to Reducing the Risk of Cognitive Decline" under the supervision of NCGG. more info >> |
|
|
国立長寿医療研究センターとエーザイ、認知機能低下リスクの低減と栄養に関するガイダンス、および 宅配食/ミールキット開発の手引きを作成し、食品関連企業へ提供開始 |
| 国立研究開発法人国立長寿医療研究センター（理事長：荒井秀典、以下 国立長寿医療研究センター）とエーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、国立長寿医療研究センターの監修のもと、エーザイが「認知機能低下リスクの低減と栄養に関するガイダンス」（以下、「ガイダンス」）および「認知機能低下リスクの低減に寄与する宅配食/ミールキット開発の手引き」（以下、「手引き」）を作成し、宅配食/ミールキットサービスをはじめとする食品関連企業への提供を開始したことをお知らせします。 more info >> |
|
| Monday, March 28, 2022 |
|
|
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor |
| Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca, Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan. more info >> |
|
|
ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得 |
| ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得 more info >> |
|
| Tuesday, March 22, 2022 |
|
|
エーザイとバイオジェン、抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブに関する最新の知見を第16回アルツハイマー・パーキンソン病学会（AD/PD(TM) 2022）において発表 |
| more info >> |
|
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
| Wednesday, March 16, 2022 |
|
|
バイオジェンとエーザイはアルツハイマー病治療薬の提携契約を変更 |
| バイオジェン・インク（Nasdaq: BIIB、本社：米国マサチューセッツ州 ケンブリッジ、CEO：ミシェル・ヴォナッソス、以下 バイオジェン）とエーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、既存のアデュカヌマブ（米国の製品名ADUHELM）のコラボレーション契約を変更したことをお知らせします。 more info >> |
|
| Tuesday, March 15, 2022 |
|
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
| Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
| Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
| Friday, March 11, 2022 |
|
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
AVIA Announces Election of Two New Board Directors
Dec 9, 2025 10:50 HKT/SGT
|
|
|
depa Announces Record-Breaking Success of gamescom asia x Thailand Game Show 2025, Generating Over THB 1.2 Billion in Economic Value
Dec 9, 2025 10:22 HKT/SGT
|
|
|
Cyara Appoints Sushil Kumar as CEO to Extend Enterprise AI Customer Experience (CX) Leadership
Dec 9, 2025 07:00 HKT/SGT
|
|
|
Indonesian Government's Swift Response in Recovering Flood-hit Sumatra
Dec 8, 2025 19:30 HKT/SGT
|
|
|
Doubleview Gold Corp. Announces Successful Completion of 2025 Drilling Season at the Hat Project, the Largest Drill Season yet with 13,290m Diamond Drill Core
Dec 8, 2025 19:09 HKT/SGT
|
|
|
三菱重工、英国初となるセメント工場向けCO2回収プラントを受注
Dec 8, 2025 18:30: JST
|
|
|
Focus Graphite Executes Funding Agreement for $14.1M under Natural Resources Canada's Global Partnerships Initiative
Dec 8, 2025 18:09 HKT/SGT
|
|
|
カスペルスキー プレミアム、マルウェアからの保護率で99.99%を記録し、AV-Comparativesのパフォーマンステストで首位を獲得
Dec 8, 2025 17:00: JST
|
|
|
Business of IP Asia Forum and Entrepreneur Day events conclude
Dec 8, 2025 16:05: JST
|
|
|
Honda Technical Support for Red Bull Powertrains in F1 Racing Concludes
Dec 8, 2025 16:34 JST
|
|
|
Business of IP Asia Forum and Entrepreneur Day events conclude
Dec 8, 2025 15:06 HKT/SGT
|
|
|
MHIET U.S. Subsidiary's Franklin Plant Celebrates 10th Anniversary
Dec 8, 2025 16:03 JST
|
|
|
佩戴疾速，畅享便捷：塔皮 科技携手阿布扎比第一银行（费斯特·阿布扎比·班克）与万事达卡（马斯特卡德）推出高性能支付腕带
Dec 8, 2025 13:49 HKT/SGT
|
|
|
TransNusa Ends 2025 With The Launch Of Four New Scheduled Direct Domestic Flights
Dec 8, 2025 10:32 HKT/SGT
|
|
|
米国株式アクティブ残高10年連続世界No.1ティー・ロウ・プライス[1]
3人に1人が「定年後も働く」- 老後資産形成のグローバル意識調査
Dec 8, 2025 10:30: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
